Compare Novartis AG (NVS) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Union Pacific Corporation — how do they compare? Novartis AG trades at $152.75 (market cap $295.37B), while Union Pacific Corporation trades at $291.87 (market cap $173.99B). The key difference: Novartis AG is the larger of the two by market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| NVS | UNP | |
|---|---|---|
Market Cap | $295.37B | $173.99B |
Sector | Health | Industrials |
52-Week High | $168.62 | $307.32 |
52-Week Low | $119.31 | $214.91 |
Enterprise Value | $336.69B | $203.04B |
Dividend Yield | 3.07% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Union Pacific (UNP) trades at $292.24, down 0.3% on the day, with a neutral technical signal. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised full-year guidance. Fundamentals remain robust with a net income margin of 28.85% and ROE of 39.7%, though valuation ratios like P/E of 23.71 are elevated. Recent news highlights a 3% dividend increase and ongoing merger developments with Norfolk Southern.
The outlook is positive, driven by service-led growth, pricing power, and efficiency gains. Key opportunities include domestic intermodal expansion and margin improvement. Risks involve high fuel costs, regulatory scrutiny of the merger, and economic sensitivity. Analyst consensus is bullish with a $334.33 price target, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
